Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last SFr.94.10 CHF
Change Today -2.65 / -2.74%
Volume 18.1K
SANN On Other Exchanges
Symbol
Exchange
SANN is not on other exchanges.
As of 11:43 AM 04/28/15 All times are local (Market data is delayed by at least 15 minutes).

santhera pharmaceuticals-reg (SANN) Snapshot

Open
SFr.97.10
Previous Close
SFr.96.75
Day High
SFr.97.15
Day Low
SFr.93.45
52 Week High
02/3/15 - SFr.119.00
52 Week Low
05/12/14 - SFr.3.61
Market Cap
462.2M
Average Volume 10 Days
20.8K
EPS TTM
SFr.-1.60
Shares Outstanding
4.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SANTHERA PHARMACEUTICALS-REG (SANN)

Related News

No related news articles were found.

santhera pharmaceuticals-reg (SANN) Related Businessweek News

No Related Businessweek News Found

santhera pharmaceuticals-reg (SANN) Details

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of mitochondrial and neuromuscular diseases in the areas of various orphan and niche indications primarily in North America and the European Union. It offers Raxone/Catena for the treatment of Leber’s Hereditary Optic Neuropathy (LHON) and Duchenne Muscular Dystrophy (DMD). The company also develops Raxone/Catena for treating patients with primary progressive Multiple Sclerosis. It also develops omigapil that is in Phase I trial for the treatment of Congenital Muscular Dystrophies. The company has a collaboration agreement with the US patient advocacy organization for a survey- based benefit/risk evaluation in DMD. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Liestal, Switzerland.

14.7 Employees
Last Reported Date: 04/14/15
Founded in 2004

santhera pharmaceuticals-reg (SANN) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: SFr.326.4K
Compensation as of Fiscal Year 2013.

santhera pharmaceuticals-reg (SANN) Key Developments

Santhera Pharmaceuticals Holding AG Proposes Amendments to the Articles of Incorporation

Santhera Pharmaceuticals Holding AG proposed amendments to the articles of incorporation with respect to authorized and conditional capital and consequence of the ordinance against excessive compensation at public corporations, and other, at the annual general meeting to be held on May 11, 2015.

Santhera Pharmaceuticals Announces Consolidated Financial Results for the Full Year 2014

Santhera Pharmaceuticals announced consolidated financial results for the full year 2014. For the year, the company reported the operating loss of CHF 7.5 million was comparable to 2013 of CHF 7.3 million. For the full-year 2014, the company reported a net loss of CHF 7.5 million compared to CHF 5.8 million including extraordinary financial income of CHF 1.5 million from the settlement of finance lease liabilities. The company reported net sales of CHF 2.591 million compared to CHF 1.319 million a year ago. Basic and diluted loss per shares was CHF 1.60 compared to CHF 1.55 a year ago. Operating cash flow was CHF 6.063 million compared to CHF 6.976 million a year ago.

Santhera Pharmaceuticals Announces Phase III Trial with Raxone/Catena

Santhera Pharmaceuticals announced that Gunnar M. Buyse, PhD, MD, Professor of Child Neurology at the University Hospitals Leuven (Belgium), and principal investigator, will present outcome data of the Phase III trial with Raxone(R)/Catena(R) (idebenone) in Duchenne Muscular Dystrophy (DMD) at the upcoming annual meeting of the American Academy of Neurology (AAN).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SANN:SW SFr.94.10 CHF -2.65

SANN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SANN.
View Industry Companies
 

Industry Analysis

SANN

Industry Average

Valuation SANN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 194.0x
Price/Book 29.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 187.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANTHERA PHARMACEUTICALS-REG, please visit www.santhera.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.